This comprehensive report analyzes the global orally administered vaccine market, projecting steady growth from 2025 through 2032. The industry is primarily driven by the rising demand for needle-free, convenient vaccination options that enhance patient compliance and simplify logistics in pediatric and developing regions. Through detailed segmentation by type, application, and geography, the study evaluates key market dynamics, competitive landscapes, and emerging opportunities. It also addresses critical challenges, including vaccine stability and regulatory complexities, to provide a nuanced outlook on the sector's future trajectory.

Market Overview

• Market Size Projection: The global Orally Administered Vaccine market is predicted to grow from US$ 2908 million in 2025 to US$ 4307 million in 2032.
• Compound Annual Growth Rate (CAGR): The market is expected to grow at a CAGR of 5.9% from 2026 to 2032.
• Biological Significance: Orally administered vaccines are of interest as they elicit both systemic and mucosal immunities; specifically, mucosal immunity can neutralize mucosa-invading pathogens before the onset of an infection.

Market Dynamics

Growth Drivers

• Demand for Convenience: Growing demand for convenient and needle-free vaccination options, particularly in pediatric and developing regions.
• Operational Advantages: Ease of administration, increased patient compliance, and simplified logistics.
• Public Health Utility: Suitability for mass vaccination programs and the ability to reach remote areas with limited healthcare infrastructure.
• Economic & Stability Factors: Potential for improved vaccine stability and reduced production costs.

Market Challenges

• Biological Hurdles: The need for enhanced vaccine stability to withstand gastrointestinal conditions.
• Efficacy Concerns: Ensuring consistent efficacy across diverse populations.
• Regulatory Barriers: Complexities in regulation and the requirement for stringent safety and efficacy data.

Strategic Success Factors for Companies

• Focus on innovative vaccine delivery technologies.
• Conduct robust clinical trials.
• Collaborate with global health agencies.
• Address public perception and trust regarding the safety and effectiveness of oral vaccines.

Report Scope and Methodology

Research Overview

LP Information, Inc. (LPI) ' newest research report, the “Orally Administered Vaccine Industry Forecast,” reviews total world Orally Administered Vaccine sales in 2025 and provides a comprehensive analysis of projected sales for 2026 through 2032. The report offers a detailed analysis in US$ millions, broken down by region, market sector, and sub-sector.

Analytical Focus

This Insight Report provides a comprehensive analysis of the global Orally Administered Vaccine landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments and M&A activity

Furthermore, the report analyzes the strategies of leading global companies, focusing on:

• Orally Administered Vaccine portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

Methodology

The study evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. The study utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to offer a nuanced view of the current state and future trajectory of the industry.

Market Segmentation

By Type

• Rotavirus Vaccine
• Cholera Vaccine
• Oral Polio Vaccine
• Other

By Application

• Public
• Private

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

The following companies have been profiled based on inputs gathered from primary experts and analysis of company coverage, product portfolios, and market penetration:

• Merck
• GSK
• Sanofi
• Lanzhou Institute
• Serum Institute
• Valneva
• Shanghai United Cell
• Bibcol
• PaxVax
• Vabiotech
• Tiantan Biological
• EuBiologics
• Panacea Biotec Ltd
• Bio-Med
• Halfkin Bio-Pharmaceuticals

Key Questions Addressed

• What is the 10-year outlook for the global Orally Administered Vaccine market?
• What factors are driving Orally Administered Vaccine market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Orally Administered Vaccine market opportunities vary by end market size?
• How does Orally Administered Vaccine break out by Type, by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Orally Administered Vaccine Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Orally Administered Vaccine by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Orally Administered Vaccine by Country/Region, 2021, 2025 & 2032

  • 2.2 Orally Administered Vaccine Segment by Type

    • 2.2.1 Rotavirus Vaccine

    • 2.2.2 Cholera Vaccine

    • 2.2.3 Oral Polio Vaccine

    • 2.2.4 Other

    • 2.2.5 Orally Administered Vaccine Sales by Type

      • 2.2.5.1 Global Orally Administered Vaccine Sales Market Share by Type (2021-2026)
      • 2.2.5.2 Global Orally Administered Vaccine Revenue and Market Share by Type (2021-2026)
      • 2.2.5.3 Global Orally Administered Vaccine Sale Price by Type (2021-2026)

  • 2.3 Orally Administered Vaccine Segment by Application

    • 2.3.1 Public

    • 2.3.2 Private

    • 2.3.3 Orally Administered Vaccine Sales by Application

      • 2.3.3.1 Global Orally Administered Vaccine Sale Market Share by Application (2021-2026)
      • 2.3.3.2 Global Orally Administered Vaccine Revenue and Market Share by Application (2021-2026)
      • 2.3.3.3 Global Orally Administered Vaccine Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Orally Administered Vaccine Breakdown Data by Company

    • 3.1.1 Global Orally Administered Vaccine Annual Sales by Company (2021-2026)

    • 3.1.2 Global Orally Administered Vaccine Sales Market Share by Company (2021-2026)

  • 3.2 Global Orally Administered Vaccine Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Orally Administered Vaccine Revenue by Company (2021-2026)

    • 3.2.2 Global Orally Administered Vaccine Revenue Market Share by Company (2021-2026)

  • 3.3 Global Orally Administered Vaccine Sale Price by Company

  • 3.4 Key Manufacturers Orally Administered Vaccine Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Orally Administered Vaccine Product Location Distribution

    • 3.4.2 Players Orally Administered Vaccine Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Orally Administered Vaccine by Geographic Region

  • 4.1 World Historic Orally Administered Vaccine Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Orally Administered Vaccine Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Orally Administered Vaccine Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Orally Administered Vaccine Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Orally Administered Vaccine Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Orally Administered Vaccine Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Orally Administered Vaccine Sales Growth

  • 4.4 APAC Orally Administered Vaccine Sales Growth

  • 4.5 Europe Orally Administered Vaccine Sales Growth

  • 4.6 Middle East & Africa Orally Administered Vaccine Sales Growth

• 5 Americas

  • 5.1 Americas Orally Administered Vaccine Sales by Country

    • 5.1.1 Americas Orally Administered Vaccine Sales by Country (2021-2026)

    • 5.1.2 Americas Orally Administered Vaccine Revenue by Country (2021-2026)

  • 5.2 Americas Orally Administered Vaccine Sales by Type (2021-2026)

  • 5.3 Americas Orally Administered Vaccine Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Orally Administered Vaccine Sales by Region

    • 6.1.1 APAC Orally Administered Vaccine Sales by Region (2021-2026)

    • 6.1.2 APAC Orally Administered Vaccine Revenue by Region (2021-2026)

  • 6.2 APAC Orally Administered Vaccine Sales by Type (2021-2026)

  • 6.3 APAC Orally Administered Vaccine Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Orally Administered Vaccine by Country

    • 7.1.1 Europe Orally Administered Vaccine Sales by Country (2021-2026)

    • 7.1.2 Europe Orally Administered Vaccine Revenue by Country (2021-2026)

  • 7.2 Europe Orally Administered Vaccine Sales by Type (2021-2026)

  • 7.3 Europe Orally Administered Vaccine Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Orally Administered Vaccine by Country

    • 8.1.1 Middle East & Africa Orally Administered Vaccine Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Orally Administered Vaccine Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Orally Administered Vaccine Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Orally Administered Vaccine Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Orally Administered Vaccine

  • 10.3 Manufacturing Process Analysis of Orally Administered Vaccine

  • 10.4 Industry Chain Structure of Orally Administered Vaccine

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Orally Administered Vaccine Distributors

  • 11.3 Orally Administered Vaccine Customer

• 12 World Forecast Review for Orally Administered Vaccine by Geographic Region

  • 12.1 Global Orally Administered Vaccine Market Size Forecast by Region

    • 12.1.1 Global Orally Administered Vaccine Forecast by Region (2027-2032)

    • 12.1.2 Global Orally Administered Vaccine Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Orally Administered Vaccine Forecast by Type (2027-2032)

  • 12.7 Global Orally Administered Vaccine Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Merck

    • 13.1.1 Merck Company Information

    • 13.1.2 Merck Orally Administered Vaccine Product Portfolios and Specifications

    • 13.1.3 Merck Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Merck Main Business Overview

    • 13.1.5 Merck Latest Developments

  • 13.2 GSK

    • 13.2.1 GSK Company Information

    • 13.2.2 GSK Orally Administered Vaccine Product Portfolios and Specifications

    • 13.2.3 GSK Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 GSK Main Business Overview

    • 13.2.5 GSK Latest Developments

  • 13.3 Sanofi

    • 13.3.1 Sanofi Company Information

    • 13.3.2 Sanofi Orally Administered Vaccine Product Portfolios and Specifications

    • 13.3.3 Sanofi Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Sanofi Main Business Overview

    • 13.3.5 Sanofi Latest Developments

  • 13.4 Lanzhou Institute

    • 13.4.1 Lanzhou Institute Company Information

    • 13.4.2 Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications

    • 13.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Lanzhou Institute Main Business Overview

    • 13.4.5 Lanzhou Institute Latest Developments

  • 13.5 Serum Institute

    • 13.5.1 Serum Institute Company Information

    • 13.5.2 Serum Institute Orally Administered Vaccine Product Portfolios and Specifications

    • 13.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Serum Institute Main Business Overview

    • 13.5.5 Serum Institute Latest Developments

  • 13.6 Valneva

    • 13.6.1 Valneva Company Information

    • 13.6.2 Valneva Orally Administered Vaccine Product Portfolios and Specifications

    • 13.6.3 Valneva Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Valneva Main Business Overview

    • 13.6.5 Valneva Latest Developments

  • 13.7 Shanghai United Cell

    • 13.7.1 Shanghai United Cell Company Information

    • 13.7.2 Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications

    • 13.7.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Shanghai United Cell Main Business Overview

    • 13.7.5 Shanghai United Cell Latest Developments

  • 13.8 Bibcol

    • 13.8.1 Bibcol Company Information

    • 13.8.2 Bibcol Orally Administered Vaccine Product Portfolios and Specifications

    • 13.8.3 Bibcol Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Bibcol Main Business Overview

    • 13.8.5 Bibcol Latest Developments

  • 13.9 PaxVax

    • 13.9.1 PaxVax Company Information

    • 13.9.2 PaxVax Orally Administered Vaccine Product Portfolios and Specifications

    • 13.9.3 PaxVax Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 PaxVax Main Business Overview

    • 13.9.5 PaxVax Latest Developments

  • 13.10 Vabiotech

    • 13.10.1 Vabiotech Company Information

    • 13.10.2 Vabiotech Orally Administered Vaccine Product Portfolios and Specifications

    • 13.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 Vabiotech Main Business Overview

    • 13.10.5 Vabiotech Latest Developments

  • 13.11 Tiantan Biological

    • 13.11.1 Tiantan Biological Company Information

    • 13.11.2 Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications

    • 13.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 Tiantan Biological Main Business Overview

    • 13.11.5 Tiantan Biological Latest Developments

  • 13.12 EuBiologics

    • 13.12.1 EuBiologics Company Information

    • 13.12.2 EuBiologics Orally Administered Vaccine Product Portfolios and Specifications

    • 13.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.12.4 EuBiologics Main Business Overview

    • 13.12.5 EuBiologics Latest Developments

  • 13.13 Panacea Biotec Ltd

    • 13.13.1 Panacea Biotec Ltd Company Information

    • 13.13.2 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications

    • 13.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.13.4 Panacea Biotec Ltd Main Business Overview

    • 13.13.5 Panacea Biotec Ltd Latest Developments

  • 13.14 Bio-Med

    • 13.14.1 Bio-Med Company Information

    • 13.14.2 Bio-Med Orally Administered Vaccine Product Portfolios and Specifications

    • 13.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.14.4 Bio-Med Main Business Overview

    • 13.14.5 Bio-Med Latest Developments

  • 13.15 Halfkin Bio-Pharmaceuticals

    • 13.15.1 Halfkin Bio-Pharmaceuticals Company Information

    • 13.15.2 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications

    • 13.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview

    • 13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments

• 14 Research Findings and Conclusion